

Dobrin Nedelkov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10392837/publications.pdf>

Version: 2024-02-01

66
papers

3,113
citations

109321

35
h-index

155660

55
g-index

68
all docs

68
docs citations

68
times ranked

2145
citing authors

#	ARTICLE	IF	CITATIONS
1	Biosensor chip mass spectrometry: A chip-based proteomics approach. <i>Electrophoresis</i> , 2000, 21, 1155-1163.	2.4	196
2	Investigating diversity in human plasma proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10852-10857.	7.1	169
3	Surface Plasmon Resonance Imaging Measurements of Antibody Arrays for the Multiplexed Detection of Low Molecular Weight Protein Biomarkers. <i>Analytical Chemistry</i> , 2006, 78, 6504-6510.	6.5	159
4	Multitoxin biosensorâ€™mass spectrometry analysis: a new approach for rapid, real-time, sensitive analysis of staphylococcal toxins in food. <i>International Journal of Food Microbiology</i> , 2000, 60, 1-13.	4.7	115
5	Surface plasmon resonance mass spectrometry: recent progress and outlooks. <i>Trends in Biotechnology</i> , 2003, 21, 301-305.	9.3	107
6	Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. <i>Clinical Biochemistry</i> , 2013, 46, 399-410.	1.9	98
7	Determination of Î²-2 Microglobulin Levels in Plasma Using a High-Throughput Mass Spectrometric Immunoassay System. <i>Analytical Chemistry</i> , 2001, 73, 3294-3299.	6.5	86
8	Quantitative Mass Spectrometric Immunoassay of Insulin Like Growth Factor 1. <i>Journal of Proteome Research</i> , 2004, 3, 851-855.	3.7	78
9	High-Throughput Protein Characterization Using Mass Spectrometric Immunoassay. <i>Analytical Biochemistry</i> , 2002, 301, 49-56.	2.4	76
10	Detection of novel truncated forms of human serum amyloid A protein in human plasma. <i>FEBS Letters</i> , 2003, 537, 166-170.	2.8	76
11	Detection and Quantification of Î²-2-Microglobulin Using Mass Spectrometric Immunoassay. <i>Analytical Biochemistry</i> , 2001, 289, 26-35.	2.4	73
12	Population Proteomics. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1811-1818.	3.8	73
13	High-Throughput Comprehensive Analysis of Human Plasma Proteins: A Step toward Population Proteomics. <i>Analytical Chemistry</i> , 2004, 76, 1733-1737.	6.5	70
14	Development of Surface Plasmon Resonance Mass Spectrometry Array Platform. <i>Analytical Chemistry</i> , 2007, 79, 5987-5990.	6.5	70
15	Practical considerations in BIA/MS: optimizing the biosensor-mass spectrometry interface. <i>Journal of Molecular Recognition</i> , 2000, 13, 140-145.	2.1	69
16	Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. <i>Journal of Lipid Research</i> , 2003, 44, 630-639.	4.2	66
17	Comparative Urine Protein Phenotyping Using Mass Spectrometric Immunoassay. <i>Journal of Proteome Research</i> , 2003, 2, 191-197.	3.7	65
18	Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. <i>Biochemical and Biophysical Research Communications</i> , 2002, 297, 401-405.	2.1	64

#	ARTICLE	IF	CITATIONS
19	Detection of Staphylococcal Enterotoxin B via Biomolecular Interaction Analysis Mass Spectrometry. Applied and Environmental Microbiology, 2003, 69, 5212-5215.	3.1	64
20	Analysis of human urine protein biomarkers via biomolecular interaction analysis mass spectrometry. American Journal of Kidney Diseases, 2001, 38, 481-487.	1.9	59
21	Analysis of native proteins from biological fluids by biomolecular interaction analysis mass spectrometry (BIA/MS): exploring the limit of detection, identification of non-specific binding and detection of multi-protein complexes. Biosensors and Bioelectronics, 2001, 16, 1071-1078.	10.1	54
22	An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM). Proteomics, 2014, 14, 1445-1456.	2.2	54
23	Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics, 2004, 4, 1825-1829.	2.2	53
24	Investigation of Human Protein Variants and Their Frequency in the General Population. Molecular and Cellular Proteomics, 2007, 6, 1183-1187.	3.8	51
25	Mass Spectrometric Immunoassay for Quantitative Determination of Protein Biomarker Isoforms. Journal of Proteome Research, 2010, 9, 5969-5973.	3.7	49
26	Multiplexed Mass Spectrometric Immunoassay in Biomarker Research: A Novel Approach to the Determination of a Myocardial Infarct. Journal of Proteome Research, 2006, 5, 2928-2934.	3.7	48
27	Parallel Workflow for High-Throughput (>1,000 Samples/Day) Quantitative Analysis of Human Insulin-Like Growth Factor 1 Using Mass Spectrometric Immunoassay. PLoS ONE, 2014, 9, e92801.	2.5	48
28	Quantitative Multiplexed C-Reactive Protein Mass Spectrometric Immunoassay. Journal of Proteome Research, 2006, 5, 1682-1687.	3.7	47
29	Population proteomics: addressing protein diversity in humans. Expert Review of Proteomics, 2005, 2, 315-324.	3.0	45
30	Peer Reviewed: Biomolecular Interaction Analysis Mass Spectrometry.. Analytical Chemistry, 2000, 72, 404 A-411 A.	6.5	44
31	Mass spectrometry-based immunoassays for the next phase of clinical applications. Expert Review of Proteomics, 2006, 3, 631-640.	3.0	43
32	Population proteomics: Investigation of protein diversity in human populations. Proteomics, 2008, 8, 779-786.	2.2	42
33	Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods, 2015, 81, 86-92.	3.8	42
34	Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1. PLoS ONE, 2013, 8, e81125.	2.5	40
35	Quantitative Mass Spectrometry Evaluation of Human Retinol Binding Protein 4 and Related Variants. PLoS ONE, 2011, 6, e17282.	2.5	37
36	Exploring the limit of detection in biomolecular interaction analysis mass spectrometry (BIA/MS): detection of attomole amounts of native proteins present in complex biological mixtures. Analytica Chimica Acta, 2000, 423, 1-7.	5.4	36

#	ARTICLE	IF	CITATIONS
37	Design and use of multi-affinity surfaces in biomolecular interaction analysis-mass spectrometry (BIA/MS): a step toward the design of SPR/MS arrays. <i>Journal of Molecular Recognition</i> , 2003, 16, 15-19.	2.1	32
38	Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry. <i>FEBS Letters</i> , 2003, 536, 130-134.	2.8	31
39	Targeted quantitative mass spectrometric immunoassay for human protein variants. <i>Proteome Science</i> , 2011, 9, 19.	1.7	31
40	Serum Amyloid A Truncations in Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015, 10, e0115320.	2.5	30
41	Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms. <i>Proteomes</i> , 2016, 4, 13.	3.5	29
42	Delineation of <i>in vivo</i> assembled multiprotein complexes via biomolecular interaction analysis mass spectrometry. <i>Proteomics</i> , 2001, 1, 1441-1446.	2.2	28
43	Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. <i>Proteomics</i> , 2011, 11, 3633-3641.	2.2	28
44	Surface plasmon resonance-enabled mass spectrometry arrays. <i>Electrophoresis</i> , 2006, 27, 3671-3675.	2.4	27
45	Delineating protein-protein interactions via biomolecular interaction analysis-mass spectrometry. <i>Journal of Molecular Recognition</i> , 2003, 16, 9-14.	2.1	26
46	Development of Recombinant-Based Mass Spectrometric Immunoassay with Application to Resistin Expression Profiling. <i>Analytical Chemistry</i> , 2006, 78, 3271-3276.	6.5	25
47	Mass Spectrometric Immunoassay for the qualitative and quantitative analysis of the cytokine Macrophage Migration Inhibitory Factor (MIF). <i>Proteome Science</i> , 2014, 12, 52.	1.7	25
48	Top-down mass spectrometric immunoassay for human insulin and its therapeutic analogs. <i>Journal of Proteomics</i> , 2018, 175, 27-33.	2.4	25
49	Selected expression profiling of full-length proteins and their variants in human plasma. <i>Clinical Proteomics</i> , 2004, 1, 7-16.	2.1	23
50	High-throughput MS-based protein phenotyping: Application to haptoglobin. <i>Proteomics</i> , 2005, 5, 5002-5007.	2.2	21
51	Delineation of Concentration Ranges and Longitudinal Changes of Human Plasma Protein Variants. <i>PLoS ONE</i> , 2014, 9, e100713.	2.5	20
52	Mass spectrometry-based protein assays for <i>in vitro</i> diagnostic testing. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 235-239.	3.1	19
53	Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants. <i>Journal of Proteomics</i> , 2015, 116, 15-23.	2.4	18
54	Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms. <i>Bioanalysis</i> , 2016, 8, 1623-1633.	1.5	17

#	ARTICLE	IF	CITATIONS
55	Integration of SPR Biosensors with Mass Spectrometry (SPR-MS). <i>Methods in Molecular Biology</i> , 2010, 627, 261-268.	0.9	16
56	High-Throughput Affinity Mass Spectrometry. , 2006, 328, 141-150.		12
57	Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes. <i>Proteomes</i> , 2017, 5, 27.	3.5	12
58	Surface Plasmon Resonance Mass Spectrometry for Protein Analysis. , 2006, 328, 131-140.		11
59	Human proteoforms as new targets for clinical mass spectrometry protein tests. <i>Expert Review of Proteomics</i> , 2017, 14, 691-699.	3.0	11
60	Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. <i>Journal of Clinical Lipidology</i> , 2016, 10, 808-815.	1.5	10
61	Development of quantitative mass spectrometric immunoassay for serum amyloid A. <i>Biomarkers</i> , 2016, 21, 743-751.	1.9	8
62	Association of cystatin C proteoforms with estimated glomerular filtration rate. <i>Clinical Mass Spectrometry</i> , 2016, 1, 27-31.	1.9	5
63	Proteomics and Host-Pathogen Interactions. , 2011, , 263-303.		4
64	Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 858-863.	2.3	2
65	Volumetric Mass Spectrometry Protein Arrays. <i>Methods in Molecular Biology</i> , 2007, 382, 333-343.	0.9	1
66	Proteomics of Human Urine. , 2007, , 225-268.		0